Oxford Immunotec Announces Launch of the Accutix(TM) Brand
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the Accutix brand for its tick-borne disease offering.
"Incorporating the feedback of our customers was a key consideration in our selection of a new brand name," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "Tick-borne disease specialists value the accuracy of our tests and the history and credibility of our lab in helping them diagnose Lyme and other tick-borne diseases. The Accutix name embodies these qualities and will assist us in building a market leadership position in the tick-borne disease diagnostics market."
The Accutix brand aligns Oxford Immunotec's tick-borne disease offering, which includes over 20 testing options targeting eight tick-borne diseases, under a unified name. The Company will continue to develop new assays for both existing and emerging tick-borne diseases under the Accutix brand.
Tick-borne diseases is the collective name for diseases passed to humans through the bite of an infected tick. As reported by the CDC, the most common tick-borne disease in the United States is Lyme disease, and it is estimated that over 300,000 people are diagnosed with the disease each year. Other tick-borne diseases include Rocky Mountain Spotted Fever, babesiosis, ehrlichiosis, anaplasmosis, Powassan disease, tick-borne relapsing fever and tularemia. According to data maintained by CDC, the incidence of all tick-borne diseases has increased steadily each year and the number of reported cases of Lyme disease more than doubled from 2001 through 2016.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries:
Head of Strategy and Investor Relations
Tel: +1 (508) 556-1377
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/be24233e-c09e-4c14-beea-21ba6c7ecc4d
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial4.6.2020 19:10:28 CEST | Press release
Bagsværd, Denmark, 4 June 2020 – Novo Nordisk today announced headline results from STEP 1, a phase 3a trial in the STEP programme. STEP 1 is a 68-week randomised, double-blind, multicentre, placebo-controlled weight management trial. The trial investigated the efficacy and safety of once-weekly subcutaneous (sc) semaglutide 2.4 mg on body weight over 68 weeks compared to placebo in 1,961 adults with obesity or overweight with comorbidities, both in conjunction with lifestyle intervention. The STEP 1 trial met both primary endpoints. In all people randomised1, a statistically significant and superior reduction in body weight was achieved with sc semaglutide 2.4 mg compared to placebo after 68 weeks. People treated with sc semaglutide 2.4 mg achieved a weight loss of 14.9%, from a mean baseline body weight of 105.3 kg, compared to a 2.4% weight loss with placebo. In addition, 86.4% of those who received sc semaglutide 2.4 mg reached a weight loss of 5% or more after 68 weeks, compared t
Scandinavian Tobacco Group A/S: Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities4.6.2020 18:00:00 CEST | Press release
Company Announcement No. 15/2020 Copenhagen, 4 June 2020 Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Claus Gregersen 2. Reason for the notification a) Position/title Member of the Board of Directors b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Purchase of shares c) Price(s) and volume(s) Price(s)Volume(s)98.8
Scandinavian Tobacco Group A/S: Indberetning og offentliggørelse af transaktioner udført af person med ledelsesansvar4.6.2020 18:00:00 CEST | pressemeddelelse
Selskabsmeddelelse Nr. 15/2020 København, den 4. juni 2020 Indberetning og offentliggørelse af transaktioner udført af person med ledelsesansvar 1. Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne a) Navn Claus Gregersen 2. Årsag til indberetningen a) Stilling/titel Medlem af bestyrelsen b) Første indberetning/ændring Første indberetning 3. Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførende a) Navn Scandinavian Tobacco Group A/S b) LEI-kode 5299003KG4JS99TRML67 4. Nærmere oplysninger om transaktionen/transaktionerne: gentages for (i) hver type instrument, (ii) hver type transaktion, (iii) hver dato og (iv) hvert sted, hvor der er udført transaktioner a) Beskrivelse af det finansielle instrument, instrumenttypen Identifikationskode Aktier DK0060696300 – STG b) Transaktionens art Køb af aktier c) Pris(er) og mængde(r) Pris(er)Mængde(r)98,8849 aktier98
Maha Energy AB (publ) Announce May Production Volumes4.6.2020 17:00:00 CEST | Press release
Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm June 4, 2020 Maha Energy AB (publ) Announce May Production Volumes Production Volumes The Company's aggregate sales production for the month of May totaled 106,2481 barrels of oil and 52.765 million scf of gas for a combined average production of approximately 3,711 BOE/day2, before royalties and taxes. The month of May saw increasing gas sales at Tie as a new gas end-user started taking deliveries allowing for higher oil production. Further at both Tie and Tartaruga stations, oil production was somewhat affected due to temporary surface jet pump maintenance issues which were resolved during the month. Despite the pump issues and continuing Covid-19 movement restrictions, production and off-take volumes in Brazil remain stable. 1 Subject to minor standard industry adjustments at the time of custody transfer. 2 Barrels of oil equivalent ("BOE") conversion ratio of 6,000 scf: 1 bbl is us
Cyber Security 1 AB: CYBER1 Confirms Publication Date for the 2019 Annual Report4.6.2020 16:45:00 CEST | Press release
CYBER1 Confirms Publication Date for the 2019 Annual Report London United Kingdom – 04 June 2020, Cyber Security 1 AB (Publ) (“CYBER1”), (Nasdaq:CYB1, OTCQX:CYBNY), has announced a revised publication date of the 9th of June, for the 2019 Annual Report. The change in date brings the 2019 Annual Report publication in line with the Cyber Security 1 AB 2020 AGM, scheduled for Tuesday, 30 June 2020. Shareholders and key stakeholders in the interim may refer to the full year unaudited accounts, through the Q4 2019 report available on our website: www.cyber1.com The annual report once published will be available to view on the CYBER1 website. Certified Adviser Mangold Fondkommission AB is the Company’s Certified Adviser. Telephone: +46 (0)8 5030 1550 E-mail: email@example.com FOR FURTHER INFORMATION, PLEASE CONTACT: Investor Relations Contact: Tim Metcalfe / Zach Cohen CYBER1 Email: firstname.lastname@example.org ABOUT CYBER1 CYBER1 is engaged in providing cyber resilience solutions and conducts it
Auction details Inflation-linked bonds4.6.2020 16:20:00 CEST | Press release
Auction date June 11, 2020 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2027-12-01 3113SE0009548704 0.125% 750 2032-06-01 3111 SE0007045745 0.125% 250 Settlement date June 15, 2020 Bids have to be entered by 11.00 on June 11, 2020 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 email@example.com